RxDoctor Payments Data

Courtney Barrett, NP

Acute Care · Centerville, OHNPI 1336586445

Payments from drug & device makers

$3,469in general payments, 2019–2025

Across 91 payments — averaging $38.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$874
  • Sanofi$520
  • Biogen$492
  • AstraZeneca$465
  • EMD Serono, Inc.$333
  • Genentech USA, Inc.$198
  • plus $586 from 9 others

What the payments were for

  • Food & beverage$3,29595%
  • Education$1745%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,469 in reported general payments places this provider in the 90th percentile of 1,101 acute care providers in Ohio.

See all acute care providers in Ohio

Medicare billing

Part B allowed, 2024
$29,625
Medicare patients
67
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab73$680,028
MayzentSiponimod14$184,940
Rebif RebidoseInterferon Beta-1a/Albumin13$126,881
AubagioTeriflunomide13$117,229
CopaxoneGlatiramer Acetate12$83,998
Dalfampridine ErDalfampridine45$52,469
Teriflunomide35$40,523
GlatopaGlatiramer Acetate19$36,503
Baclofen207$6,008
Modafinil47$3,191
Gabapentin116$1,650
AmantadineAmantadine Hcl36$1,543
Carbamazepine ErCarbamazepine14$1,441
Pregabalin34$1,195
Oxcarbazepine12$1,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$874$184,94014 claims
SanofiAubagio$520$117,22913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,101 acute care providers in Ohio.

Other acute care in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →